Effects of the solution and first aging treatment applied to as-built and post-HIP CM247 produced via Laser Powder Bed Fusion (LPBF)

In this work CM247LC, a low weldable Ni-Based alloy, was produced using selective laser melting (SLM). Despite the initial process parameter optimization, the low defect volume fraction was still uncompliant with manufacturing standards. This condition is principally caused by the high γ’ volume fraction which strongly affects the alloy weldability. Nonetheless, a crack free condition was eventually achieved applying a γ’-sub-solvus Hot Isostatic Pressing Cycle (HIP) which lowered the defects fraction down to 0.04%. The HIP cycle also demonstrated to play an important role in the stabilization of the microstructure, considerably limiting the carbides coarsening during the following heat treatment. Apart from the effectiveness of the healing process brought by HIP, the material microstructure still needs an optimization process which will be described along this paper. In fact, the Initial microstructure obtained after the printing process (the as-built condition) as well as the one obtained after HIP (post-HIP) won’t meet the desired requirements. Namely, the dendritic and γ’ free microstructure of the asbuilt material or the one with coarse and disordered particles obtained right after HIP, still need a tailored homogenization process. This paper will show how the combined effect of the solution and first aging treatment will profoundly alter the γ’ precipitation. More specifically, here, a new heat treatment recipe was developed to promote the precipitation of ordered cuboidal primary γ’ so as to improve creep and high temperature fatigue resistance. Moreover, the use of a γ’ super-solvus temperature allowed to achieve a γ’ volume fraction as high as 73% reducing its average size to 520 nm. At the same time, such heat treatment caused a profound alteration of the crystalline structures of the material promoting a general grain coarsening and the formation of equiaxial grain

Folding mechanisms steer the amyloid fibril formation propensity of highly homologous proteins

Significant advances in the understanding of the molecular determinants of fibrillogenesis can be expected from comparative studies of the aggregation propensities of proteins with highly homologous structures but different folding pathways. Here, we fully characterize, by means of stopped-flow, T-jump, CD and DSC experiments, the unfolding mechanisms of three highly homologous proteins, zinc binding Ros87 and Ml153-149 and zinc-lacking Ml452-151. The results indicate that the three proteins significantly differ in terms of stability and (un)folding mechanisms. Particularly, Ros87 and Ml153-149 appear to be much more stable to guanidine denaturation and are characterized by folding mechanisms including the presence of an intermediate. On the other hand, metal lacking Ml452-151 folds according to a classic two-state model. Successively, we have monitored the capabilities of Ros87, Ml452-151 and Ml153-149 to form amyloid fibrils under native conditions. Particularly, we show, by CD, fluorescence, DLS, TEM and SEM experiments, that after 168 hours, amyloid formation of Ros87 has started, while Ml153-149 has formed only amorphous aggregates and Ml452-151 is still monomeric in solution. This study shows how metal binding can influence protein folding pathways and thereby control conformational accessibility to aggregation-prone states, which in turn changes aggregation kinetics, shedding light on the role of metal ions in the development of protein deposition diseases

Light-driven C–O coupling of carboxylic acids and alkyl halides over a Ni single-atom catalyst

Although visible-light-driven dual photoredox catalysis, a method that combines photoabsorbers and transition metals, has become a powerful tool to conduct coupling reactions, resource economical and scalability issues persist, owing to the use of catalysts and light absorbers that exploit critical raw materials (such as iridium complexes), and are homogeneous in nature. Here we report the merger of metallic single-atom and photoredox catalysis, in the form of a Ni atom-supported carbon nitride material, for the C–O coupling of carboxylic acids and alkyl halides. This operationally straightforward system, composed of only earth-abundant components, exhibits a wide functional group tolerance. Additionally, short reaction times, facile recovery and high catalyst stability make this method highly attractive for industrial applications

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy

The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need to identify reliable outcome measures for young boys with DMD. The aim of this study was to develop a revised version of the North Star Ambulatory Assessment (NSAA) suitable for boys between the age of 3 and 5 years by identifying age appropriate items and revising the scoring system accordingly. Using the scale in 171 controls between the age of 2.9 and 4.8 years, we identified items that were appropriate at different age points. An item was defined as age appropriate if it was completed, achieving a full score, by at least 85% of the typically developing boys at that age. At 3 years (±3months) there were only 8 items that were age appropriate, at 3 years and 6 months there were 13 items while by the age of 4 years all 17 items were appropriate. A revised version of the scale was developed with items ordered according to the age when they could be reliably performed. The application of the revised version of the scale to data collected in young DMD boys showed that very few of the DMD boys were able to complete with a full score all the age appropriate items. In conclusion, our study suggests that a revised version of the NSAA can be used in boys from the age of 3 years to obtain information on how young DMD boys acquire new abilities and how this correlates with their peers

Correction : Long term natural history data in ambulant boys with Duchenne muscular dystrophy : 36-month changes

The 6 minute walk test has been recently chosen as the primary outcome measure in international multicenter clinical trials in Duchenne muscular dystrophy ambulant patients. The aim of the study was to assess the spectrum of changes at 3 years in the individual measures, their correlation with steroid treatment, age and 6 minute walk test values at baseline. Ninety-six patients from 11 centers were assessed at baseline and 12, 24 and 36 months after baseline using the 6 minute walk test and the North Star Ambulatory Assessment. Three boys (3%) lost the ability to perform the 6 minute walk test within 12 months, another 13 between 12 and 24 months (14%) and 11 between 24 and 36 months (12%). The 6 minute walk test showed an average overall decline of 1215.8 (SD 77.3) m at 12 months, of 1258.9 (SD 125.7) m at 24 months and 12104.22 (SD 146.2) m at 36 months. The changes were significantly different in the two baseline age groups and according to the baseline 6 minute walk test values (below and above 350 m) (p<0.001). The changes were also significantly different according to steroid treatment (p\u200a=\u200a0.01). Similar findings were found for the North Star Ambulatory Assessment. These are the first 36 month longitudinal data using the 6 minute walk test and North Star Ambulatory Assessment in Duchenne muscular dystrophy. Our findings will help not only to have a better idea of the progression of the disorder but also provide reference data that can be used to compare with the results of the long term extension studies that are becoming available

Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy

Abstract The Performance of Upper Limb was specifically designed to assess upper limb function in Duchenne muscular dystrophy. The aim of this study was to assess (1) a cohort of typically developing children from the age of 3 years onwards in order to identify the age when the activities assessed in the individual items are consistently achieved, and (2) a cohort of 322 Duchenne children and young adults to establish the range of findings at different ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to 25 years old. A full score was consistently achieved by the age of 5 years. In the Duchenne cohort there was early involvement of the proximal muscles and a proximal to distal progressive involvement. The scale was capable of measuring small distal movements, related to activities of daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials

Patterns of disease progression in type 2 and 3 SMA : Implications for clinical trials

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License CC BY NC-ND 4.0 ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.The aim of the study was to establish 12-month changes in the Hammersmith Functional motor scale in a large cohort of SMA patients, to identify patterns of disease progression and the effect of different variables. 268 patients were included in this multicentric study. Their age ranged between 2.5 and 55.5 years at baseline, 68 were ambulant and 200 non-ambulant. The baseline scores ranged between 0 and 66 (mean 23.91, SD 20.09). The 12-month change was between -14 and +9 (mean -0.56, SD 2.72). Of the 268 patients, 206 (76.86%) had changes between -2 and +2 points. Ambulant and non-ambulant subjects had a different relationship between baseline values and age (p for age X ambulation interaction = 0.007). There was no association with age in ambulant subjects, while there was a significant heterogeneity at different age for non-ambulant patients (p < 0.001). The 12-month change (adjusted for baseline) was not associated with age in ambulant patients (p = 0.34), but it was significantly different among various age groups in non-ambulant patients. Our results suggest that there are different profiles of progression in ambulant and non-ambulant patients, and that age may play an important role in the progression of non-ambulant patients.Peer reviewedFinal Published versio